MATTHEW LOBOSCO: Open Payments
NPI 1487896148 · MAPLEWOOD, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,116 in 71 payments from 17 companies in 2025. Trend: 2023 $0 · 2024 $456 · 2025 $2,116
Food & beverage: $1,893Education: $223
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 14 | $607 |
| Otsuka America Pharmaceutical, Inc. | 17 | $444 |
| Lundbeck LLC | 12 | $304 |
| Almatica Pharma LLC | 6 | $137 |
| ABBVIE INC. | 4 | $126 |
| Biogen, Inc. | 3 | $87 |
| Alkermes, Inc. | 3 | $82 |
| Luye Pharma (USA) Ltd. | 2 | $48 |
| Bausch Health US, LLC | 2 | $45 |
| Vanda Pharmaceuticals Inc. | 1 | $39 |
Products named: REXULTI, AUSTEDO XR, ABILIFY ASIMTUFII, LOREEV XR, VRAYLAR, ZURZUVAE, ABILIFY MAINTENA, LYBALVI.
Industry payments across NJ — which companies pay providers there.
